Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin + cytarabine (Jazz Pharmaceuticals plc)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Vyxeos (daunorubicin + cytarabine) is a liposomal combination chemotherapy developed by Jazz Pharmaceuticals for the treatment of specific types of acute myeloid leukemia (AML). It consists of two established antineoplastic agents, daunorubicin and cytarabine, encapsulated within a liposome at a fixed 1:5 molar ratio. This specific ratio has been shown in preclinical studies to maximize synergistic cell kill. The liposomal formulation, developed using proprietary CombiPlex technology, is designed to deliver the drug combination directly to the bone marrow, where it is preferentially taken up by leukemia cells, thereby increasing efficacy and potentially reducing systemic toxicity. Daunorubicin is an anthracycline that inhibits topoisomerase II and intercalates into DNA, while cytarabine is a nucleoside analog that inhibits DNA polymerase and interferes with DNA synthesis. Vyxeos is primarily indicated for newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
- Brand names
- Vyxeos
- Other names
- daunorubicin and cytarabine liposomeliposomal daunorubicin and cytarabineCPX351CPX-351CPX 351
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on daunorubicin + cytarabine (Jazz Pharmaceuticals plc).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin + cytarabine (Jazz Pharmaceuticals plc).